Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05601128 · ClinicalTrials.gov registry record · Phase 3
A Study Evaluating the Pharmacokinetics, Efficacy, Safety and Tolerability of CABENUVA
A Phase 3 study, sponsored by Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute).
- Completed
- Registry status
- Phase 3
- Development phase
- 12
- Enrollment target
NCT05601128 is a Phase 3 study that has completed, run by Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute). The registered enrollment target is 12 participants.
The verdict
NCT05601128, a Phase 3 study, has completed, sponsored by Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of CABENUVA (Long-acting Cabotegravir Plus Long-acting Rilpivirine) in patients with HIV infection and severe renal impairment. This study is considered research and is voluntary.
Interventions
- DRUG CAB + RPV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2023-01-01 |
| Est. Completion | 2025-05-01 |
| Phase | Phase 3 |
Sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)34 total trials
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05601128
The ClinicalTrials.gov registry entry for NCT05601128 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute), which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CAB + RPV is the first listed.
NCT05601128 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05601128 about?
NCT05601128 is a clinical study titled "A Study Evaluating the Pharmacokinetics, Efficacy, Safety and Tolerability of CABENUVA". The purpose of this study is to evaluate the efficacy and safety of CABENUVA (Long-acting Cabotegravir Plus Long-acting Rilpivirine) in patients with HIV infection and severe renal impairment. This study is considered research and is voluntary.
What is the current status of trial NCT05601128?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 12 participants. The study started on 2023-01-01. Estimated completion is 2025-05-01.
What interventions are being tested in trial NCT05601128?
The interventions under investigation include: CAB + RPV (DRUG).
Who is sponsoring clinical trial NCT05601128?
This trial is sponsored by Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute), which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.